Glucose News and Research

RSS

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Diabetes is growing at an alarming rate in Canada, with an estimated 3.7 million people expected to be diagnosed by 2020. It is a progressive disease that, if not properly monitored and managed over time, will lead to serious long term complications. Canadians now have a novel treatment available to help them maintain optimal blood glucose levels. Health Canada has approved Victoza (liraglutide), the first GLP-1 analogue, for once-daily administration for the treatment of adults with type 2 diabetes to improve glycemic control in combination with metformin or metformin and a sulfonylurea.

27 May 2010

Important milestone in development of ORMD-0801 published in DOM journal

Oramed Pharmaceuticals Inc., a developer of alternative drug delivery systems, announced today that the paper entitled, "Open-label study to assess the safety and pharmacodynamics of five oral insulin formulations in healthy subjects," authored by Dr. Roy Eldor, Dr. Miriam Kidron and Dr. Ehud Arbit, was accepted and published in the Diabetes, Obesity and Metabolism journal.

26 May 2010

Intel expands availability of Intel Health Guide across Europe

Intel is expanding availability of the Intel Health Guide across Europe to help address chronic care challenges - Intel is working with strategic partners in France, Germany, Spain and The Netherlands to bring localised versions of the Intel Health Guide to market over the coming year

26 May 2010

Study finds disagreement between RA patients and doctors on assessment of disease severity

A novel study by researchers at the University of California, San Francisco found that nearly one-third of Rheumatoid Arthritis (RA) patients differed from their physicians in assessment of their disease severity. The disagreement between patient and doctor evaluation of RA activity was most prevalent in patients with depressive symptoms, and those who had poor overall function.

26 May 2010

Bayer selects Vision Chain as Enterprise Demand Signal Repository and Predictive Analytics platform

Vision Chain, Inc., the leading global provider of demand signal repository and predictive analytic solutions, announced today that Bayer Healthcare LLC, the global leader in trusted brands for healthcare and nutrition, has licensed its technology platform to analyze store-specific sales, assortments, prices, promotions and other factors to optimize go-to-market efforts with multiple retailers.

25 May 2010

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Medtronic, Inc. today announced financial results for its fourth quarter and fiscal year ended April 30, 2010.

25 May 2010

Abbott's new FreeStyle Lite blood glucose test strips receive FDA clearance

Abbott today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration for its new FreeStyle Lite blood glucose test strips. The new FreeStyle Lite test strips minimize interference during blood glucose testing and are designed to offer a better testing experience.

24 May 2010

Researchers study correlation between type 2 diabetes and increased risk of cancer

Cancer and diabetes - are risk factors the same for these two diseases? Or does diabetes cause processes in the body which promote the onset or growth of cancer? It is still unclear why diabetics have a higher rate of cancer than people who are not affected by this metabolic disorder.

21 May 2010

Pharmacist-led HBPM program improves blood pressure control

A pharmacist-led home blood pressure monitoring program supported by the American Heart Association's Heart 360 website dramatically improved blood pressure control for patients with uncontrolled hypertension, according to a study.

21 May 2010

Researchers analyze impact of health promotion program on cardiovascular disease-related medical, hospital costs

A comprehensive health promotion program reduced cardiovascular disease-related medical and hospital costs, according to a new study. CSX Transportation, a national company with 30,000 employees, developed the program in 2004 to address employees' high rates of cardiovascular disease when compared to national benchmarks and the associated higher healthcare costs.

21 May 2010

Group weight loss programs reduce risk for type 2 diabetes

The 57 million Americans currently living with "pre-diabetes" could benefit from a group weight loss program, like Weight Watchers, according to a new study published in this month's American Journal of Lifestyle Medicine. Researchers found that after a 6-month Weight Watchers group program, overweight or obese adults who attended at least two thirds of the weekly sessions, not only lost weight, but also significantly reduced fasting glucose and insulin levels - important indicators of diabetes risk.

21 May 2010

Niacin fortification foods can cause obesity

Dietary factors have long been known to play a major role in the development of obesity. The global increasing prevalence of obesity suggests that there should be some common changes in diet worldwide.

21 May 2010

Weight Watchers group program helps obese adults lose weight, reduce glucose and insulin levels

20 May 2010

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Dr. Barry Reiner announced that he is now recruiting children and adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

20 May 2010

Diabetic patients with limited health literacy are at higher risk for hypoglycemia: Study

People with diabetes who have limited health literacy are at higher risk for hypoglycemia or low blood sugar, according to a new study from researchers at the University of California, San Francisco and the Kaiser Permanente Division of Research in Oakland, CA.

19 May 2010

PET scanning provides great insight into immune response

A commonly used probe for Positron Emission Tomography scanning and a new probe developed by researchers at UCLA reveal different functions in diverse cells of the immune system, providing a non-invasive and much clearer picture of an immune response in action.

19 May 2010

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Dr. Bruce Bode announced today that he is now recruiting adults with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes.

18 May 2010

Sleep apnea increases insulin resistance: Study

Sleep apnea may cause metabolic changes that increase insulin resistance, according to researchers from the University of Pittsburgh Medical Center. The intermittent hypoxia associated with sleep apnea causes a distinct drop in insulin sensitivity in mice, even though chronic hypoxia, such as that associated with high altitude, did not.

18 May 2010

PositiveID announces early completion of iGlucose system prototype development

PositiveID Corporation announced today that it has completed development of the initial prototype of its iGlucose system, creating a small cradle that connects to any data-capable glucose meter to automatically communicate a diabetic's blood sugar readings to the iGlucose online database.

18 May 2010

Echo Therapeutics first-quarter net loss increases to $1.9 million

Echo Therapeutics, Inc., a company developing its needle-free Symphony™ tCGM System as a non-invasive, wireless, transdermal continuous glucose monitoring (tCGM) system and its Prelude™ SkinPrep System for transdermal drug delivery, today announced financial results for the period ended March 31, 2010.

18 May 2010

Glucose News and Research

Health Canada approves Victoza for treatment of adults with type 2 diabetes

Important milestone in development of ORMD-0801 published in DOM journal

Intel expands availability of Intel Health Guide across Europe

Study finds disagreement between RA patients and doctors on assessment of disease severity

Bayer selects Vision Chain as Enterprise Demand Signal Repository and Predictive Analytics platform

Medtronic fiscal year 2010 revenue up 8% to $15.817 billion

Abbott's new FreeStyle Lite blood glucose test strips receive FDA clearance

Researchers study correlation between type 2 diabetes and increased risk of cancer

Pharmacist-led HBPM program improves blood pressure control

Researchers analyze impact of health promotion program on cardiovascular disease-related medical, hospital costs

Group weight loss programs reduce risk for type 2 diabetes

Niacin fortification foods can cause obesity

Weight Watchers group program helps obese adults lose weight, reduce glucose and insulin levels

Recruitment of children and adults with type 1 diabetes commences in Protege Encore teplizumab trial

Diabetic patients with limited health literacy are at higher risk for hypoglycemia: Study

PET scanning provides great insight into immune response

Adults with newly diagnosed type 1 diabetes recruited for Protege Encore clinical trial

Sleep apnea increases insulin resistance: Study

PositiveID announces early completion of iGlucose system prototype development

Echo Therapeutics first-quarter net loss increases to $1.9 million

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News